首页> 外文OA文献 >Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

【2h】

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

机译：将Azelnidipine重新定位为靶向CD47 /siRPα和TIGIT / PVR癌的双重抑制剂，用于癌症免疫治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V. Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages [J] . Pedro Cabrales Translational Oncology . 2019,第4期

机译：RRx-001通过下调癌细胞上的CD47和单核细胞/巨噬细胞上的SIRP-α充当双重小分子检查点抑制剂
2. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR [J] . Xiuman Zhou, Jiangfeng Du, Hongfei Wang, Cell Communication and Signaling . 2020,第1期

机译：通过阻断免疫检查点TIGIT / PVR的相互作用来重新定位癌症免疫疗法
3. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer [J] . Stamm Hauke, Wellbrock Jasmin, Fiedler Walter Mammalian genome: official journal of the International Mammalian Genome Society . 2018,第11a12期

机译：PVR / PVRL2与TIGIT / DNAM-1的相互作用作为新型免疫检查点轴和癌症治疗靶标
4. Repositioning drugs for breast cancer based on the identification of cancer related signaling pathways [C] . Wang Yin-Ying, Zhang Xiao-Dong, Yan-Fen Dai, Chinese Control Conference . 2013

机译：基于与癌症相关的信号通路的鉴定，重新定位乳腺癌药物
5. Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness : targeted genes are involved in bladder cancer pathogenesis [D] . SUGAWARA, Sho 2019

机译：miR-223双链体的双链（miR-223-5p和miR-223-3p）抑制癌细胞侵袭性：靶向基因参与膀胱癌的发病机理
6. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy [O] . Xiuman Zhou, Ling Jiao, Yuzhen Qian, 2021

机译：将Azelnidipine重新定位为靶向CD47 /siRPα和TIGIT / PVR癌的双重抑制剂用于癌症免疫治疗
7. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice [O] . David Kung-Chun Chiu, Vincent Wai-Hin Yuen, Jacinth Wing-Sum Cheu, 2020

机译：肝细胞癌细胞上调PVRL1，稳定PVR并通过TIGIT抑制细胞毒性T细胞反应，以介导小鼠肿瘤抑制剂的肿瘤抗性

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

著录项

引文网络

相似文献

相关主题

期刊订阅